PRISM MediaWire

PRISM MarketView

MindMed Closes Out 2023 with Positive Phase 2b Results for Generalized Anxiety Treatment

New York, N.Y., February 28, 2024 - PRISM MediaWire - PRISM MarketView - Mind Medicine (MindMed) Inc. (Nasdaq: MNMD) has announced its financial results for the year ended December 31, 2023, closing out a “highly productive” year with positive Phase 2b results for MM120 ...

28 February 2024

PRISM MarketView

PRISM Rare Disease Spotlight: Capricor Therapeutics Advances Treatment for Duchenne Muscular Dystrophy

New York, N.Y., February 28, 2024 - PRISM MediaWire - PRISM MarketView - Rare disease company, Capricor Therapeutics (Nasdaq: CAPR), has been granted an in-person Type-B meeting with the FDA to discuss chemistry, manufacturing and controls (CMC) plans for commercial laun...

28 February 2024

PRISM MarketView

PRISM Rare Disease Spotlight: Voyager Therapeutics Selects Development Candidate for Friedreich’s Ataxia, Triggers $5M Milestone Payment

New York, N.Y., February 27, 2024 - PRISM MediaWire - PRISM MarketView - Voyager Therapeutics (Nasdaq: VYGR) has selected a lead development candidate in its Friedreich’s Ataxia (FA) program. The company expects the program to advance into first-in-human clinical trials ...

27 February 2024

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

Chief Medical Officer Dr. Michael Chancellor will discuss hemorrhagic cystitis and the company’s lead candidate, LP-10

20 February 2024

Oncocyte to Present at the Sequire Investor Summit in Puerto Rico

IRVINE, CA, January 16, 2024 - PRISM MediaWire - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, today announced that CEO Josh Riggs will be presenting a corporate overview at the upcoming Sequire Investor Summit 2024. The conference is scheduled for...

16 January 2024

Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished

Lipella Granted Two Orphan Drug Designations by FDA

20 December 2023

MyMD Tackles Rheumatoid Arthritis with Launch of Phase 2 Trial in Early 2024

NEW YORK, NY, December 11, 2023 - The FDA has cleared an Investigational New Drug Application (IND) for MyMD Pharmaceuticals (Nasdaq: MYMD) to initiate a Phase 2 clinical trial of oral MYMD-1® as a treatment for rheumatoid arthritis (RA). The company plans to launch the...

11 December 2023

PRISM MarketView Biotech Index Top Mover Spotlight: Kamada (KMDA)

NEW YORK, NY, December 07, 2023 - PRISM MediaWire -PRISM MarketView, a leading provider of unbiased market insight and company news, highlights Kamada Ltd. (Nasdaq: KMDA), a commercial-stage global biopharmaceutical company with a portfolio of products for rare and serio...

7 December 2023

Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

-Significant unmet need for regulated product in $2B US testing market--Opportunity for expedited pathway for kitted product in development-

6 December 2023

PRISM MARKETVIEW HIGHLIGHTS ALTIMMUNE’S POSITIVE TOPLINE RESULTS IN OBESITY DRUG TRIAL

NEW YORK, NY, December 05, 2023 - PRISM MediaWire -PRISM MarketView, a leading provider of unbiased market insight and company news, highlights Altimmune, Inc. (Nasdaq: ALT) which has reported positive topline results from its 48-week MOMENTUM Phase 2 obesity trial of pe...

5 December 2023